These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21734183)

  • 61. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Walking activity in a large cohort of boys with Duchenne muscular dystrophy.
    Lott DJ; Taivassalo T; Senesac CR; Willcocks RJ; Harrington AM; Zilke K; Cunkle H; Powers C; Finanger EL; Rooney WD; Tennekoon GI; Vandenborne K
    Muscle Nerve; 2021 Feb; 63(2):192-198. PubMed ID: 33188573
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cross-sectional evaluation of electrical impedance myography and quantitative ultrasound for the assessment of Duchenne muscular dystrophy in a clinical trial setting.
    Rutkove SB; Geisbush TR; Mijailovic A; Shklyar I; Pasternak A; Visyak N; Wu JS; Zaidman C; Darras BT
    Pediatr Neurol; 2014 Jul; 51(1):88-92. PubMed ID: 24814059
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neck flexor muscle strength and its relation with functional performance in Duchenne muscular dystrophy.
    Bozgeyik S; Alemdaroğlu İ; Bulut N; Yılmaz Ö; Karaduman A
    Eur J Paediatr Neurol; 2017 May; 21(3):494-499. PubMed ID: 28034620
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Longitudinal Evaluation of Muscle Composition Using Magnetic Resonance in 4 Boys With Duchenne Muscular Dystrophy: Case Series.
    Senesac CR; Lott DJ; Forbes SC; Mathur S; Arpan I; Senesac ES; Walter GA; Vandenborne K
    Phys Ther; 2015 Jul; 95(7):978-88. PubMed ID: 25592189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
    Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
    Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
    Romano A; Favetta M; Schirinzi T; Summa S; Minosse S; D'Amico A; Catteruccia M; Petrarca M; Castelli E; Bertini E; Vasco G
    Neuromuscul Disord; 2019 Dec; 29(12):920-929. PubMed ID: 31791868
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.
    Mok E; Letellier G; Cuisset JM; Denjean A; Gottrand F; Alberti C; Hankard R
    PLoS One; 2009; 4(5):e5448. PubMed ID: 19421321
    [TBL] [Abstract][Full Text] [Related]  

  • 72. T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.
    Yin L; Xie ZY; Xu HY; Zheng SS; Wang ZX; Xiao JX; Yuan Y
    Curr Med Sci; 2019 Feb; 39(1):138-145. PubMed ID: 30868504
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.
    Pradhan S; Ghosh D; Srivastava NK; Kumar A; Mittal B; Pandey CM; Singh U
    J Neurol; 2006 Oct; 253(10):1309-16. PubMed ID: 16786214
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
    Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
    Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study.
    Fischer D; Hafner P; Rubino D; Schmid M; Neuhaus C; Jung H; Bieri O; Haas T; Gloor M; Fischmann A; Bonati U
    Neuromuscul Disord; 2016 Jul; 26(7):414-22. PubMed ID: 27209345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies.
    Bello L; Campadello P; Barp A; Fanin M; Semplicini C; Sorarù G; Caumo L; Calore C; Angelini C; Pegoraro E
    Sci Rep; 2016 Sep; 6():32439. PubMed ID: 27582364
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naïve Patients with Duchenne Muscular Dystrophy.
    Sawnani H; Horn PS; Wong B; Darmahkasih A; Rybalsky I; Shellenbarger KC; Tian C; Rutter MM; Simakajornboon N; Amin R; Gurbani N; Pascoe J; Burrows C; Khirani S; Amaddeo A; Fauroux B
    J Pediatr; 2019 Jul; 210():194-200.e2. PubMed ID: 30955791
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How do physical capacity, fatigue and performance differ in children with duchenne muscular dystrophy compared with their healthy peers?
    Mutlu A; Alkan H; Fırat T; Karaduman AA; Yilmaz OT
    Neurosciences (Riyadh); 2018 Jan; 23(1):39-45. PubMed ID: 29455220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.